Highlights from the 22nd International AIDS Conference (AIDS 2018), 22-27 July 2018, Amsterdam, the Netherlands

Christina K Psomas; Sarah Fidler; Malcolm Macartney; Richard Jeffreys; Lisa Reilly; Simon Collins; Santiago Moreno; Jean-Pierre Routy; Alexander Pasternak; Sabine Kinloch-de Loës

Highlights from the 22nd International AIDS Conference (AIDS 2018), 22-27 July 2018, Amsterdam, the Netherlands

J Virus Erad. 2018 Oct 1;4(4):238-247.

Authors

Affiliations

¹ Department of Infectious Diseases and Internal Medicine, European Hospital, Marseille, France.
² Imperial College London, London, UK.
³ Janssen, Pharmaceutical Companies of Johnson and Johnson. Canterbury, UK.
⁴ Treatment Action Group (TAG), USA.
⁵ , US Military HIV Research Program, Bethesda, MA, USA.
⁶ HIV i-Base, London, UK.
⁷ Ramon y Cajal Hospital, Madrid, Spain.
⁸ McGill University Health Centre, Montreal, Canada.
⁹ Department of Medical Microbiology, Laboratory of Experimental Virology, AMC, Amsterdam, the Netherlands.
¹⁰ Department of Infection and Immunity, Royal Free Hospital and University College, London, UK.

PMID: 30515304
PMCID: PMC6248835

Abstract

Important data on the social, epidemiological and clinical aspects of HIV-1, comorbidities and hepatitis as well as data on novel antiretroviral agents and the cure agenda were presented at AIDS 2018. This report covers some of the highlights.

Publication types

Editorial

Grants and funding

MR/L00528X/1/MRC_/Medical Research Council/United Kingdom